IWPC (International Warfarin Pharmacogenetics Consortium). 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753–764.

Kangelaris, K. N., S. Bent, R. L. Nussbaum, D. A. Garcia, and J. A. Tice. 2009. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 24(5):656–664.

Limdi, N. A., G. McGwin, J. A. Goldstein, T. M. Beasley, D. K. Arnett, B. K. Adler, M. F. Baird, and R. T Acton. 2008. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321.

Meckley, L. M., J. M. Gudgeon, J. L. Anderson, M. S. Williams, and D. L. Veenstra. 2010. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1):61–74.

Mvundura, M., S. D. Grosse, H. Hampel, and G. E. Palomaki. 2010. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12(2):93–104.

Patrick, A. R., J. Avorn, and N. K. Choudhry. 2009. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2(5):429–436.

Rieder M. J., A. P. Reiner, B. F. Gage, D. A. Nickerson, C. S. Eby, H. L. McLeod, D. K. Blough, K. E. Thummel, D. L. Veenstra, and A. E. Rettie. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285–2293.

USPSTF (U.S. Preventive Services Task Force). 1996. Guide to Clinical Preventive Services, 2nd Edition. Available at www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hscps2ed1996 (accessed May 18, 2010).

Veenstra, D. L. 2007. The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost 5(9):1974–1975.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement